• Acetylcysteine: modern possibilities for use in practice of pediatricians and family doctors

Acetylcysteine: modern possibilities for use in practice of pediatricians and family doctors

SOVREMENNAYA PEDIATRIYA.2018.7(95):69-76; doi 10.15574/SP.2018.95.69

Beketova G. V., Soldatova O. V.
Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

The article presents modern data on therapeutic possibilities of using acetylcysteine in practice of pediatricians and family doctors. Its mucolytic, antioxidant, anti-inflammatory, anti-infectious, pulmonary-protective, anti-carcinogenic and anti$toxic properties are described. The use of acetylcysteine has been studied in acute, prolonged, recurrent and chronic respiratory pathology accompanied by the formation of viscous sputum; in inflammatory and non$inflammatory diseases developing as a result of free radicals accumulation and decrease in glutathione synthesis; as well as a detoxifier and a universal antidote for various poisonings and paracetamol overdose.

Key words: pharmacological effects, acetylcysteine, children.

REFERENCES

1. Batagov SYa. (2014). Atsetiltsistein v lechenii infektsiy nizhnih dyihatelnyih putey u vzroslyih. Lechaschiy vrach. 10: 21—27.

2. Volkov IK. (2011). Medikamentoznaya terapiya kashlya u detey. Pediatriya. Zhurnal im. G.N. Speranskogo. https://cyberleninka.ru/article/n/me-dikamentoznaya-terapiya-kashlya-u-detey

3. Havrysiuk VK. (2011). Fybrozyruiushchye alveolytы: dyahnostyka y pryntsypы terapyy. Klinichna imunolohiia. Alerholohiia. Infektolohiia. Spetsvypusk: 5—12. https://kiai.com.ua/ru-issue-article-637/Fibrozi-ruyushchie-alveolity-diagnostika-i-principy-terapii

4. Davyidova VM. (2010). Interstitsialnyie bolezni legkih u detey. http://mfvt.ru/intersticialnye-bolezni-legkix-u-detej/

5. Kosenkova TV, Bulatova EM, Rezvantsev MV, Tyukavina AV. (2011). Ispolzovanie N-atsetiltsisteina v kompleksnom lechenii zabolevaniy nizhnih dyihatelnyih putey. Rossiyskiy vestnik perinatologii i pediatrii. 6. https://cyberleninka.ru/article/n/ispolzovanie-n-atsetilt-sisteina-v-kompleksnom-lechenii-zabolevaniy-nizhnih-dyhatelnyh-putey-u-detey

6. Simonova OI, Gorinova YuV. (2014). Sravnitelnaya harakteristika izvestnyih mukolitikov v bazisnoy terapii mukovistsidoza u detey. Pediatricheskaya farmakologiya. 11(6): 96—103. https://cyberleninka.ru/article/n/sravnitelnye-harakteristiki-izvestnyh-mukolitikov-v-bazisnoy-terapii-mukovistsidoza-u-detey.

7. Simonova OI. (2010). Osobennosti primeneniya i effektivnost N-atsetiltsisteina pri respiratornoy patologii u detey. https://medi.ru/info/6798/

8. Simonova OI. (2013). Mukolitiki v pediatricheskoy praktike: ratsionalnyiy vyibor, lechebnyie effektyi i osobennosti terapii. Voprosyi sovremennoy pediatrii. 12(4):136—141.

9. Soroka ND. (2008). Mukoliticheskaya terapiya zatyazhnyih variantov techeniya zabolevaniy organov dyihaniya u detey. Vopr. sovr. pediatrii. 7 (4): 111—115.

10. Soroka ND. N-atsetiltsistein (NAS) (2013). Novyie vozmozhnosti v lechenii i profilaktike bronholegochnyih zabolevaniy u detey. Effektivnaya farmakoterapiya. Pediatriya. 1. http://umedp.ru/articles/natsetiltsistein_nas_novye_vozmozhnosti_v_lechenii_i_profilaktike_bronkho_legochnykh_zabolevaniy_u_de.htm

11. Chikina SYu, Chuchalin AG. (2013). N-atsetiltsistein: Vse li vozmozhnosti myi ispolzuem // Prakticheskaya pulmonologiya. https://cyberleninka.ru/article/n/n-atsetiltsistein-vse-li-ozmozhnosti-my-ispolzuem

12. Allen J, Bradley RD. (2011, Sep). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J. Altern Complement Med. 17(9):82733. PubMed: PM21875351

13. Beloqui О, Prieto J, Suarez M et al. (1993). N-acetylcysteine enhances the response to inrerferon-alpha in chronic hepatitis C: a pilot study. J. Inrerferon Res. 13: 279—282.

14. Bonifacio SL, Glass HC, Peloquin S, Ferriero DM. (2011). A new neurological focus in neonatal intensive care. Nat. Rev. Neurol. 7:485—494. https://doi.org/10.1038/nrneurol.2011.119; PMid:21808297

15. Cammarota, Branca G, Ardito F, Sanguinetti M, Iarino G, Clanci R, Torelli R et al. (2010). Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin. Gastroenterol. Hepatol. 8:817—820. https://doi.org/10.1016/j.cgh.2010.05.006; PMid:20478402

16. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. (2015). Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 24: 451—461. https://doi.org/10.1183/16000617.00002215; PMid:26324807

17. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P et al. (2015). Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 147(4): 894—942. https://doi.org/10.1378/chest.14-1676; PMid:25321320 PMCid:PMC4388124

18. Dinicola S, Grazia S DE, Carlomagno G, Pintucc JP. (2014). N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. European Review for Medical and Pharmacological Sciences. 18: 2942—2948. PMid:25339490

19. Ebrahimil M, Mousavi SR, Toussi AG, Reihani H, Bagherian F. (2015). Comparing the Therapeutic Effectiveness of N-acetylcysteine with the Combination of N-acetyl-Cysteine and Cimetidine in Acute Acetaminophen Toxicity: A Double-Blinded Clinical Trial. Electronic Physician (ISSN: 2008—5842). http://www.ephysician.ir

20. El-Feky MA, El-Rehewy MS, Hassan MA, Abolella HA, Abd El-Bake RM, Gad GF. (2009). Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. Pol J Microbiol. 58:261—267. PMid:19899620

21. Fiorentini С, Falzano L, Rivabene R, Fabbri A, Malorni W. (1999). N-acetylcysteine protects epithelial cells against the oxidative imbalance due со Clostridium difficile toxins. FEBS Lett. 453(1—2): 124—8.

22. Frank F S Daly, John S Fountain, Lindsay Murray, Andis Graudins, Nicholas A Buckle. (2008, March). Guidelines for the management of paracetamol poisoning in Australia and New Zealand – explanation and elaboration A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. The Medical Journal of Australia. 188; 5: 296—301.

23. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. (2007). N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol. 20: 349—354. https://doi.org/10.1177/039463200702000215; PMid:17624247

24. Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl Jr J (2012). N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem. Pharmacol.79:413—420. https://doi.org/10.1016/j.bcp.2009.08.025; PMid:19732754

25. Global strategy for the diagnosis, management, and prevention of COPD: Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2014). Available from http://www.goldcopd. org/. Last accessed on April 16, 2014.

26. Gray KM, Carpenter MJ, Baker NL, Desantis SM, Kryway E, Hartwell KJ et al. (2012, Aug 1). A doubleblind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry.169(8):805—12. Pub Med: PM22706327

27. Huia DS, Leea N, Chanc PK, Beigeld JH. (2018). The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Research. 150: 202—216. https://doi.org/10.1016/j.antiviral.2018.01.002; PMid:29325970

28. Malhotra D, Th immulappa R, Navas-Acien A et al. (2008). Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med. 178:592—604. https://doi.org/10.1164/rccm.200803-380OC; PMid:18556627 PMCid:PMC2542433

29. Mауеr М, Noble М. (1994). N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer оf trophic factor-mediated cell survival in vitro. Proc Nat Acad Sci USA. 91(16): 7496—7500.

30. National Clinical Guideline Centre. Idiopathic pulmonary fibrosis. The diagnosis and management of suspected idiopathic pulmonary fibrosis (Clinical guideline; no. 163). (2013). London (UK): National Institute for Health and Care Excellence (NICE): 32.

31. Naves P, Del Prado G, Huelves L, Rodriguez-Cerrato V, Ruiz V, Ponte MC et al. (2010). Effects of human serum albumin, ibuprofen and N-acetil-L-cysteine against biofilm formation by pathogenic Escheriachia Coli strains. Journal of Hospital Infection. 76: 165—170. https://doi.org/10.1016/j.jhin.2010.05.011; PMid:20615578

32. Roederer M, Staal FJ, Ela SW, Herzenberg LA, Herzenberg LA. (1993). N-acetylcysteine: potential for AIDS therapy. Pharmacology. 46:121—129. https://doi.org/10.1159/000139037; PMid:8441760

33. WHO Model List of Essential Medicines (19th List)’ (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016

34. Yanping Pei, Huan Liu, Yi Yang, Yanwei Yang, Yang Jiao, Franklin R. Tay et al. (2017, Dec.). Biological Activities and Potential Oral Applications of N-Acetylcysteine: Progress and Prospects. Hindawi Oxidative Medicine and Cellular Longevity. Volume 2018, Article ID

35. Zhang RH, Li CH, Wang CL, Xu MJ, Xu T, Wei D, Liu BJ, Wang GH, Tian SF. (2014). N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virusinduced acute lung injury. Int Immunopharmacol. 22: 1—8. https://doi.org/10.1016/j.intimp.2014.06.013; https://doi.org/10.1016/j.intimp.2013.12.025

36. Zhang Y, Ding S, Li C, Wang Y, Chen Z, Wang Z. (2016, July 14). Effects of N-acetylcysteine treatment in acute respiratory distress syndrome. A meta-analysis. Intensive Care Unit; Departments of Hematology and Cadre Health, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China Received July 14, 2016.

Article received: Apr 17, 2018. Accepted for publication: Nov 01, 2018.